Publications by authors named "Masayuki Hino"
Comparison of HLA-haploidentical donors with post-transplant cyclophosphamide versus HLA-matched unrelated donors in peripheral blood stem cell transplantation for acute myeloid leukaemia.
Makoto Moriguchi Hirohisa Nakamae Mitsutaka Nishimoto Junichi Sugita Masamitsu Yanada Masayuki Hino Yoshinobu Kanda
Br J Haematol
December 2024
Article Synopsis
- HLA-haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide (PTCy-haplo) is becoming a safer and more available option compared to matched unrelated donor (MUD) transplants for acute myeloid leukemia (AML).
- * A nationwide study found that while PTCy-haplo has a slower hematopoietic recovery and higher infection-related deaths, it also shows lower rates of severe graft-versus-host disease (GVHD) compared to ATG-free MUD transplants.
- * Overall survival rates were similar across all transplant types, suggesting that PTCy-haplo could be a viable option for AML patients lacking an HLA-matched donor.
Article Synopsis
- Acute lymphoblastic leukemia (ALL) has poor outcomes when it relapses after stem cell transplants, but blinatumomab, a new treatment, shows promise, especially for advanced B-cell ALL.
- The case study highlights a 56-year-old woman who achieved a third complete remission (CR) with two cycles of blinatumomab after developing isolated extramedullary relapse (EMR) post-transplant.
- The patient remained free of complications and experienced a confirmed 2-year treatment-free remission, suggesting that blinatumomab is an effective option for treating EMR of B-ALL after allo-HCT due to its association with lower tumor burdens.
The prognosis for multiple myeloma (MM) patients has improved with the advent of new drugs, but the prognosis with renal impairment (RI) is poor. The choice of treatment in such cases is critical, but there are no set criteria. We examined the impact of RI on initial therapy in transplant-ineligible MM patients.
View Article and Find Full Text PDFArticle Synopsis
- Traditional relapse prediction models for post-transplant patients don't adapt based on new information collected after the transplant, making them less effective for treatment adjustments.
- This study focused on creating a dynamic relapse prediction model specifically for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients after allogeneic hematopoietic cell transplantation (allo-HCT), utilizing WT1mRNA levels from blood tests.
- The new model demonstrated significantly better predictive performance compared to older models, allowing for real-time predictions of relapse risk and is accessible through a user-friendly web application.
Article Synopsis
- - A 55-year-old man with a history of allo-HCT for myelodysplastic syndrome developed late-onset idiopathic pneumonia syndrome (IPS) after experiencing acute respiratory distress and skin GVHD flare-up.
- - Despite multiple tests showing no infections and a poor response to standard steroid treatment, the patient improved significantly after receiving eight infusions of mesenchymal stem cells (MSCs), successfully preventing IPS recurrence for over a year.
- - This case reinforces recent preclinical findings suggesting that MSC infusion could be a promising new treatment for late-onset IPS, which traditionally has seen poor outcomes.
Article Synopsis
- * In the trial, patients were given either momelotinib or ruxolitinib for 24 weeks, measuring spleen volume reduction, overall symptom improvement, and transfusion needs as key outcomes.
- * Results showed momelotinib had a slightly better spleen response rate (50% vs. 44.4%) and much higher symptom improvement (33.3% vs. 0%), with a significant reduction in the need for blood
Article Synopsis
- * A study examined immune cell types and immunoglobulin levels in 39 patients who survived more than a year post-transplant, revealing significant differences based on the type of GVHD prophylaxis used.
- * Results indicated that patients receiving posttransplantation cyclophosphamide (PTCy) had better B-cell recovery and higher serum IgG levels compared to those treated conventionally, suggesting PTCy could help mitigate cGVHD.
Article Synopsis
- * Research found that E. faecalis avoids elimination and proliferates in the intestines by forming biofilms instead of gaining drug-resistance genes, complicating treatment options.
- * An enzyme derived from E. faecalis-specific bacteriophages demonstrated effectiveness against biofilm-forming E. faecalis, leading to reduced pathogen levels and improved survival in gnotobiotic mice with aGVHD, suggesting
Article Synopsis
- Traditional phone surveys for tracking health after peripheral blood stem cell harvest (PBSCH) are inefficient, prompting the creation of a web-based donor app for better patient-reported outcomes (ePRO).* -
- A study compared the donor app to phone surveys, discovering that app users reported their health status more frequently and required less follow-up time from healthcare professionals.* -
- Results indicated that the app yields more detailed health data without adding extra strain on donors or healthcare providers, showing promise for improving monitoring processes.*
Article Synopsis
- * A study of 69 MDS patients undergoing their first allo-HSCT found that having SIADs before the transplant significantly increases the risk of death (HR, 3.36; p = 0.009).
- * Patients with SIADs faced a higher likelihood of developing serious complications like endothelial dysfunction syndrome, which contributed to early mortality after allo-HSCT.
Article Synopsis
- Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a serious complication following allogeneic hematopoietic cell transplantation (allo-HCT), with a significant need for identifying high-risk patients prior to the procedure.
- A study of 252 patients found that higher serum autotaxin (ATX) levels before conditioning were linked to an increased incidence of VOD/SOS, showing that patients with elevated ATX had a 22.7% incidence compared to just 3.5% in those with normal levels.
- Elevated baseline ATX was determined to be an independent risk factor for VOD/SOS, indicating its potential as a valuable predictive marker for assessing risk in patients undergoing allo
Article Synopsis
- Elotuzumab is sometimes used for multiple myeloma treatment after daratumumab, but its effectiveness in this sequence is under-researched.
- A study found that patients receiving elotuzumab after daratumumab had significantly worse overall survival and time to next treatment compared to those who hadn’t previously used daratumumab.
- Results indicated that elotuzumab should ideally be administered at least 180 days after daratumumab to improve patient outcomes, suggesting that treatments without monoclonal antibodies might be a better option following daratumumab regimens.
Article Synopsis
- - The study examines how the HLA-B leader dimorphism (either methionine or threonine at position -21) affects outcomes in patients who underwent a specific type of stem cell transplant (PTCy-haplo) using posttransplant cyclophosphamide (PTCy).
- - Results showed that in patients receiving low doses of PTCy, having the methionine (M+) genotype correlated with poorer overall survival, while in the high-dose group, this genotype was linked to a reduced risk of relapse.
- - The research concludes that the HLA-B leader genotype's effects are influenced by the PTCy dose and highlights the need for further studies to explore the biological mechanisms behind these findings.
Lymphoproliferative disorders (LPDs) are serious complications that arise in patients with rheumatoid arthritis (RA) receiving immunosuppressive drugs (ISDs). Here, we reported a 73-year-old woman diagnosed with RA at 60 years of age and treated with methotrexate, bucillamine, prednisolone, and infliximab. She was referred to our hospital, Osaka Metropolitan University Hospital, with general malaise, pancytopenia, a right adrenal mass, and enlarged periaortic lymph nodes.
View Article and Find Full Text PDFArticle Synopsis
- Hepatomegaly, or enlarged liver, is an important extramedullary disease symptom in patients with hematological cancers but its role before allogeneic hematopoietic stem cell transplantation (allo-HCT) is not fully understood.
- A study of 140 patients with acute leukemia and myelodysplastic syndrome indicated that higher liver index (LI) ratios based on height were linked to an increased risk of relapse after allo-HCT, particularly in patients not in complete remission (NonCR).
- The analysis revealed that while the LI/height ratio was a significant predictor of relapse in NonCR patients, it did not show the same effect in patients who achieved complete remission (CR), suggesting the need for further investigation into
Article Synopsis
- A study compared the survival outcomes of hematopoietic cell transplants using either mismatched unrelated donors (MMUD) or cord blood (CB) under specific reduced-intensity conditioning methods, finding no significant previous differences reported.* -
- The MMUD group showed lower rates of severe acute graft-versus-host disease (GVHD) and non-relapse mortality, alongside better overall survival rates at 5 years compared to the CB group (62% vs. 31%).* -
- The results suggest that MMUD transplants, especially with improved GVHD prevention methods, may be a better option for older patients or those with additional health issues.*
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide versus HLA-Matched Unrelated Donor Transplantation for Myelodysplastic Syndrome.
Yosuke Nakaya Hideo Koh Takaaki Konuma Yoshimitsu Shimomura Ken Ishiyama Masayuki Hino Yoshinobu Kanda
Transplant Cell Ther
March 2024
Allogeneic hematopoietic cell transplantation (allo-HCT) is the sole curative therapy for myelodysplastic syndrome (MDS). In the absence of an HLA-matched sibling donor, an HLA-matched unrelated donor (MUD) is considered the leading candidate. However, in recent decades, the alternative donor pool has been extended to HLA-haploidentical donors, especially with the development of graft-versus-host disease (GVHD) prophylaxis using post-transplantation cyclophosphamide (PTCy).
View Article and Find Full Text PDFArticle Synopsis
- Blastobotrys mokoenaii is a rare yeast linked to invasive fungal infections, especially in immunocompromised individuals, such as those with acute myeloid leukemia (AML).
- A case study details a 46-year-old man with AML who developed a B. mokoenaii infection after a second stem cell transplant, leading to his death from multiorgan failure.
- The yeast was misidentified in routine tests but confirmed through DNA sequencing, highlighting the importance of advanced diagnostic methods in recognizing rare fungal pathogens.
Hyperviscosity syndrome (HVS) is a complication of monoclonal plasma cell tumors. The frequency of HVS depends on the type of monoclonal protein. Immunoglobulin M (IgM) is more closely associated with HVS than IgG, and among IgG subclass monoclonal proteins, IgG3 is most frequently associated with HVS.
View Article and Find Full Text PDF